|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
AXSM $13.00 -0.24 (-1.81%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 400 Million
EPS -0.32 P/E Ratio 0.00
Previous Earnings Wed, Oct 17, 2018
Latest Earnings Fri, Nov 9, 2018
Dividend Pay Date --
Dividend History --
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.